Abstract
Antiangiogenesis is an efficient therapy for eliminating colon cancers, but because of recurrence it remains only palliative. We hypothesized that certain populations of tumor cells resist antiangiogenesis-induced apoptosis and explored the underlying mechanism. We demonstrated that the CD133+ population of cells in colon cancer is resistant to anti-angiogenesis therapy. Additionally, we identified an anti-apoptotic signaling pathway responsible for this resistance involving PP2A, p38MAPK, MAPKAPK2, and Hsp27. Thus, this pathway may offer a new avenue to develop target therapy for colorectal cancer.
Original language | English |
---|---|
Pages (from-to) | 226-234 |
Number of pages | 9 |
Journal | Cancer Letters |
Volume | 328 |
Issue number | 2 |
DOIs | |
State | Published - 28 Jan 2013 |
Keywords
- Avastin
- Cancer stem cells
- Colon cancer
- Hypoxia
- Serum-free